PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129032
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129032
Serological Testing Market size was valued at US$ 19,051.3 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.
Serological testing involves laboratory methods that detect antibodies, antigens, or markers of immune response in biological specimens. The principal technological basis consists of ELISA, chemiluminescence, immunochromatography, and other formats of immunoassay. Its purchasing environment spans clinical laboratories, blood and plasma screening, public health surveillance, autoimmune diagnostics, infectious disease testing, and specialized biomarker assessment. Thus, the market combines recurring consumables and reagents with analyzers that are increasingly automated, focusing on throughput, traceability, and standardized interpretation. In the year 2025, the FDA had one clearance for a serology test related to COVID-19, alongside biological device clearances that involved serological tests for syphilis and cytomegalovirus, highlighting the ongoing regulatory focus on antibody-based diagnostics. This results in a market with broader assay alongside increasingly integrated laboratory workflows.
Serological Testing Market- Market Dynamics
Expansion of Standardized Serological Surveillance Infrastructure
A key demand mechanism is the institutionalization of serological testing in infectious disease surveillance networks, where reproducibility and external quality assessment increasingly drive laboratory procurement. The National Center for Vector-Borne Diseases Control has reported 869 Sentinel Surveillance Hospitals in 2025, linked with 27 Apex Referral Laboratories for diagnostic support for dengue and chikungunya. The program also supplies standardized IgM ELISA kits through the National Institute of Virology, creating an ongoing demand for validated reagents and compatible testing workflows. Such networks expand serology beyond episodic clinical testing into structured surveillance, proficiency assessment, and centralized quality control. For suppliers, this favors assays that are standardized in terms of performance and can be deployed in a scalable laboratory fashion rather than as standalone diagnostic products.
The Global Serological Testing Market is segmented on the basis of Product Type, Application, End User, Technology, and Region.
By product type, consumables and reagents are the recurring layer of analysis for serology testing, with the instruments representing the environment wherein such tests are carried out, analyzed, and recorded. This difference is important commercially, as labs today analyze the two in terms of a workflow rather than as separate purchases. The choice of reagent affects the specificity of the analysis, calibration stability, and the range of assays offered, while that of the instrument affects automation, throughput, handling, and connectivity. The launch of the Roche 2025 Elecsys PRO-C3 is a case in point, as the assay takes 18 minutes to produce results using compatible cobas analyzers. Therefore, the competitive edge depends on the compatibility of the assay and the instrument configuration.
By application, the demand created by application requirements becomes heterogeneous since there will be a fundamental need for antibody and antigen testing to address different questions posed in relation to autoimmune diseases, infectious diseases, oncology, endocrinology, toxicology, and many others. Testing for infectious diseases is associated with surveillance and profiling immune responses, while applications related to autoimmune and endocrine disorders depend strongly on analytical specificity and accurate measurement of biomarkers. The development of the IDS i20, which is set to launch in 2025 from Revvity, exemplifies this trend. The automated platform allows processing of 20 analytes in six diagnostic specialties, including endocrinology and testing for autoimmune and infectious diseases simultaneously. This means that diversity in applications has led to the consolidation of specialized serological workloads into flexible systems rather than dedicated testing systems.
Serological Testing Market- Geographical Insights
The key significance of North America lies in the advanced state of laboratory infrastructures, regulatory systems, and a large existing base to support immunoassays for diagnostic purposes. There are advanced capacities in public health laboratories as well as commercial clinical laboratories in the United States, thus forming a situation where assay validation and regulatory approval affect purchase decisions. According to the Centers for Disease Control and Prevention report released in April 2025, there were more than 200 laboratories and 1,700 scientists working in its laboratory network, engaged in surveillance, reference diagnostics, and laboratory services. Thus, the market in the region not only depends on the amount of testing but is also determined by the technical level of laboratories and their operations.
The EU's unique contribution to combating infectious diseases comes in the form of harmonizing surveillance and cross-border laboratory standards. The first six EU Reference Laboratories (RRLs) for public health opened in January 2025, covering antimicrobial resistance, vector-borne viral pathogens, emerging and zoonotic pathogens, Legionella, and diphtheria and pertussis. Each of these RRLs aims to boost diagnostic capabilities, standardize comparable laboratory procedures, and support surveillance and reporting functions within participating states. Serological test suppliers can expect that this infrastructure will create an increased need for standardized assays and quality-controlled lab processes that enable consistent performance across countries. As such, the EU's impact is felt less in a specific need for disease-testing products and more in regulatory harmonization and public health diagnostic coordination, which drives the demand for standardized and traceable lab procedures.
The competition in the market revolves more around the capability of companies to offer wide assay menus alongside the analytical infrastructure and automation of the system. In the case of Roche, its ability to integrate Elecsys immunoassay and cobas laboratory systems distinguishes it from others. On the other hand, Revvity has an edge because of the wide EUROIMMUN menu ranging from autoimmune to infectious disease and endocrinology diagnostics. Siemens Healthineers combines immunoassay instrumentation with customized test workflows. According to Roche, more than 4,500 Roche instruments have been installed at the United States' clinical laboratories by 2025 and form an existing infrastructure where new assay products can be integrated. The installed base advantage shows why competition is no longer limited to just the characteristics of the assay itself but revolves around the aspects of platform compatibility, menu growth, automation, and the capability to add new biomarkers without affecting lab infrastructure.
In March 2025, Revvity launched the EUROIMMUN Anti-Measles Virus ELISA 2.0 (IgG) with CE marking, thus adding a new assay to the company's serology product range that includes dried blood spots, as well as serum and plasma. The new assay was referred to as the first in the list of other serological tests being validated on dried blood spots.
In October 2025, Roche obtained the CE Mark for Elecsys Dengue Ag, a completely automated, high-throughput immunoassay for acute dengue infection diagnosis. Clinical evaluation showed that the test has 94.90% clinical sensitivity and 99.96% relative specificity.